Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | PRKDC | P78527 | 1/20 | 0.60 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24913028 | 0.94 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30216301 | 0.94 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24913414 | 0.94 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912742 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30216403 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24913413 | 0.90 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912807 | 0.90 | PIK3CA (0.67) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912824 | 0.90 | PIK3CA (0.67) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24913041 | 0.90 | PIK3CA (0.67) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912663 | 0.90 | PIK3CA (0.67) | PIK3CAPIK3CBMTORPRKDCPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885MTOR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.